Your browser doesn't support javascript.
loading
The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis.
Hou, Min; Xing, Haiyan; He, Shuangshuang; Yang, Xue; Peng, Dan; Li, Yang; Zhang, Qing; Zhang, Pan; Ma, Yunqi; Li, Juan; Shan, Jinlu; Liu, Yao.
Afiliação
  • Hou M; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Xing H; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • He S; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Yang X; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Peng D; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Li Y; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Zhang Q; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Zhang P; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Ma Y; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Li J; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Shan J; Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Liu Y; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
J Oncol ; 2022: 7733251, 2022.
Article em En | MEDLINE | ID: mdl-36124031
ABSTRACT

Background:

Sex, age, and International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic risk may influence the immune response. Nonetheless, the correlation between these factors and the survival benefits of immune-based combination therapies in patients with metastatic renal cell carcinoma (mRCC) is controversial and undefined. As a result, the purpose of this research is to evaluate the potential differences of immune-based combination therapies on survival benefits from mRCC subgroups.

Methods:

PubMed, Cochrane Library, Embase, and http//www.clinicaltrials.gov were searched from inception to March 17, 2022. Randomized clinical trials (RCTs) comparing overall survival (OS) or progression-free survival (PFS) in patients with mRCC treated by immune-based combinations vs. contemporary first-line therapies were included.

Results:

Five RCTs with a total of 4206 subjects were included. An OS and PFS benefit of immune-based combinations were found for patients of different sex, age, and IMDC intermediate/poor risk. No obvious difference in relative PFS benefit from immune-based combinations over the control group was found in patients of different genders (P=0.71, I2 = 0%), ages (P=0.55, I2 = 0%), or IMDC prognostic risks (P=0.38, I2 = 0%). However, the difference in OS benefit was significant regarding age (P=0.009, I2 = 85.5%) and IMDC prognostic risk (P=0.004, I2 = 82.2%).

Conclusions:

This meta-analysis found that immune-based combination therapies should not be restricted to certain patients with mRCC in gender categories. However, age and IMDC prognostic risk of mRCC patients are associated with different outcomes of OS and thus help identify those patients most probably to benefit from immune-based combination therapies.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: J Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: J Oncol Ano de publicação: 2022 Tipo de documento: Article